174 related articles for article (PubMed ID: 25582508)
1. Metabolomic discovery of novel urinary galabiosylceramide analogs as Fabry disease biomarkers.
Boutin M; Auray-Blais C
J Am Soc Mass Spectrom; 2015 Mar; 26(3):499-510. PubMed ID: 25582508
[TBL] [Abstract][Full Text] [Related]
2. Novel gb(3) isoforms detected in urine of fabry disease patients: a metabolomic study.
Auray-Blais C; Boutin M
Curr Med Chem; 2012; 19(19):3241-52. PubMed ID: 22612706
[TBL] [Abstract][Full Text] [Related]
3. A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers.
Dupont FO; Gagnon R; Boutin M; Auray-Blais C
Curr Med Chem; 2013; 20(2):280-8. PubMed ID: 23092136
[TBL] [Abstract][Full Text] [Related]
4. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics.
Auray-Blais C; Boutin M; Gagnon R; Dupont FO; Lavoie P; Clarke JT
Anal Chem; 2012 Mar; 84(6):2745-53. PubMed ID: 22309310
[TBL] [Abstract][Full Text] [Related]
5. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry.
Lavoie P; Boutin M; Auray-Blais C
Anal Chem; 2013 Feb; 85(3):1743-52. PubMed ID: 23248976
[TBL] [Abstract][Full Text] [Related]
6. Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients.
Boutin M; Menkovic I; Martineau T; Vaillancourt-Lavigueur V; Toupin A; Auray-Blais C
Anal Chem; 2017 Dec; 89(24):13382-13390. PubMed ID: 29099167
[TBL] [Abstract][Full Text] [Related]
7. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
[TBL] [Abstract][Full Text] [Related]
8. Analysis of globotriaosylceramide (Gb
Toupin A; Lavoie P; Arthus MF; Abaoui M; Boutin M; Fortier C; Ménard C; Bichet DG; Auray-Blais C
Anal Chim Acta; 2018 Jul; 1015():35-49. PubMed ID: 29530250
[TBL] [Abstract][Full Text] [Related]
9. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.
Manwaring V; Boutin M; Auray-Blais C
Anal Chem; 2013 Oct; 85(19):9039-48. PubMed ID: 23968398
[TBL] [Abstract][Full Text] [Related]
10. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
[TBL] [Abstract][Full Text] [Related]
11. Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients.
Heywood WE; Doykov I; Spiewak J; Hallqvist J; Mills K; Nowak A
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2726-2735. PubMed ID: 31319156
[TBL] [Abstract][Full Text] [Related]
12. Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry.
Lavoie P; Boutin M; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.22.1-17.22.12. PubMed ID: 27367162
[TBL] [Abstract][Full Text] [Related]
13. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
Boutin M; Auray-Blais C
Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980
[TBL] [Abstract][Full Text] [Related]
14. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
Boutin M; Lavoie P; Menkovic I; Toupin A; Abaoui M; Elidrissi-Elawad M; Arthus MF; Fortier C; Ménard C; Maranda B; Bichet DG; Auray-Blais C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854306
[TBL] [Abstract][Full Text] [Related]
15. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
Auray-Blais C; Blais CM; Ramaswami U; Boutin M; Germain DP; Dyack S; Bodamer O; Pintos-Morell G; Clarke JT; Bichet DG; Warnock DG; Echevarria L; West ML; Lavoie P
Clin Chim Acta; 2015 Jan; 438():195-204. PubMed ID: 25149322
[TBL] [Abstract][Full Text] [Related]
16. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease.
Mills K; Morris P; Lee P; Vellodi A; Waldek S; Young E; Winchester B
J Inherit Metab Dis; 2005; 28(1):35-48. PubMed ID: 15702404
[TBL] [Abstract][Full Text] [Related]
17. Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice.
Durant B; Forni S; Sweetman L; Brignol N; Meng XL; Benjamin ER; Schiffmann R; Shen JS
J Lipid Res; 2011 Sep; 52(9):1742-6. PubMed ID: 21747096
[TBL] [Abstract][Full Text] [Related]
18. LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease.
Boutin M; Gagnon R; Lavoie P; Auray-Blais C
Clin Chim Acta; 2012 Dec; 414():273-80. PubMed ID: 23041216
[TBL] [Abstract][Full Text] [Related]
19. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?
Auray-Blais C; Ntwari A; Clarke JT; Warnock DG; Oliveira JP; Young SP; Millington DS; Bichet DG; Sirrs S; West ML; Casey R; Hwu WL; Keutzer JM; Zhang XK; Gagnon R
Clin Chim Acta; 2010 Dec; 411(23-24):1906-14. PubMed ID: 20716442
[TBL] [Abstract][Full Text] [Related]
20. Tandem Mass Spectrometry Quantitation of Lyso-Gb3 and Six Related Analogs in Plasma for Fabry Disease Patients.
Boutin M; Lavoie P; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.23.1-17.23.9. PubMed ID: 27367163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
